• Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead Realasset Realasset
moneycontrol.com

Home » News » Business

May 24, 2012, 12.45 AM | Source: Moneycontrol.com

Aurobindo Pharma gets US FDA nod for generic HIV drug

Aurobindo Pharma on Wednesday said its tentatively approved abbreviated new drug applications for Nevirapine Tablets 200mg and Nevirapine oral suspension have received final approval from US Food and Drug Administration (FDA).

Like this story, share it with millions of investors on M3

Aurobindo Pharma gets US FDA nod for generic HIV drug

Aurobindo Pharma on Wednesday said its tentatively approved abbreviated new drug applications for Nevirapine Tablets 200mg and Nevirapine oral suspension have received final approval from US Food and Drug Administration (FDA).

Post Your Comments

Share Cancel

Moneycontrol Bureau

Aurobindo Pharma on Wednesday said its tentatively approved abbreviated new drug applications for Nevirapine Tablets 200mg and Nevirapine oral suspension have received final approval from US Food and Drug Administration (FDA).

Aurobindo's Nevirapine tablets and oral suspension are generic equivalent of Boehringer Ingelheim Pharmaceutical Inc's Viramune tablets and oral suspension. The drug is used as a part of antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected adults.

The two products had a market size of about USD 125 million for year ended Dec 2011, the company said, citing IMS Health data.

Aurobindo said both its products have been approved out of Unit III formulations facility in Hyderabad and will launched soon.

It now has 125 final ANDA approvals and 26 tentative approvals  from US FDA.

Aurobindo Pharma shares were up 1.4% at Rs 111.70 on NSE in afternoon trade.

Aurobindo Pharm stock price

On February 09, 2016, at 09:16 hrs Aurobindo Pharma was quoting at Rs 736.00, down Rs 10.5, or 1.41 percent. The 52-week high of the share was Rs 891.50 and the 52-week low was Rs 490.50.


The company's trailing 12-month (TTM) EPS was at Rs 25.26 per share as per the quarter ended September 2015. The stock's price-to-earnings (P/E) ratio was 29.14. The latest book value of the company is Rs 94.54 per share. At current value, the price-to-book value of the company is 7.79.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Aurobindo Pharma gets US FDA nod for generic HIV drug
New Member
0 Followers

Price when posted: BSE: Rs746.50 ( 0.00 % ), NSE: Rs. 745.20 ( 0.00 % )

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login